EDSA Company Profile and Key Details

EDSA has shown mixed momentum, losing -1.35% over the past week and -38.07% over the past quarter, though year-to-date performance is up 2.82%. Short-term trend indicators are bullishly aligned (SMA20 38.43%, SMA50 17.22%, SMA200 -20.39%). The stock’s 14-day RSI is 62.64 (firm momentum), while the ATR of 0.21 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -47.49% below its high and over 115.28% above its low. Average 10-day trading volume of 51.64 thousand shares is below the 3-month average of 514.18 thousand, indicating normal recent market interest.

Edesa Biotech, Inc. generated EPS of -$1.15 over the past year. Five-year average earnings growth is -11.35%. Wall Street analysts project EPS growth of -1.04% annually over the next five years. The latest quarter delivered EPS of -$0.49. The next quarter is forecast at -$0.26. Next year's EPS is expected at $59.29. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $5.00 to $5.00. The high target offers -26.58% upside. The low target suggests -26.58% downside. The mean target is $5.00. This offers -26.58% upside. Edesa Biotech, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 14, 2026, missed forecasts by 104.17%. The prior quarter beat by 104.17%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in May 14, 2025.

Edesa Biotech, Inc. has 7.04 million shares outstanding. The public float is 4.28 million shares, elevated short interest at 0.12% of float. This equals 7.09 thousand shares. The short ratio is 0.26 days. Institutional investors hold 41.92% of the float. Insiders own 28.55%. Pardeep Nijhawan Medicine Professional Corp holds 594.81 thousand shares, Nijhawan Pardeep has 402.70 thousand shares and Brooks Michael J has 226.87 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Edesa Biotech, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.90. This means the shares are trading above this model’s fair value.

Edesa Biotech, Inc. (NASDAQ:EDSA) closed at $6.81 USD, losing -$0.20 (-2.85%) from the previous close of $7.01. The stock is currently mid-range between its 52-week high and low $0.72 and $20.32. With a market capitalization of about $65.60 million, Edesa Biotech, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.05). Key stats such as the average daily volume over the past year has been around 517.01 thousand shares, volume is running light vs its 52-week average. Headquartered in Markham, ON, Edesa Biotech, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Pardeep Nijhawan, the company employs approximately 17 people and listed since June 21, 2010. Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate.

Edesa Biotech, Inc. trades at a P/E ratio of -5.1, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 5.53 trading at moderately above to book value. The P/FCF stands at -8.6, also below market averages.

Our AI price prediction model suggests that Edesa Biotech, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -8.52%, with price expected at $6.23 by July 27, 2026, within a range of $4.51 to $7.78 3-Month Outlook: Projected rise of 299.27%, reaching $27.19 by October 08, 2026, with a range of $26.96 to $27.41. 1-Year Outlook: Projected gain of 275.77%, with price at $25.59 by July 13, 2027, within a range of $26.48 to $27.82.

Edesa Biotech, Inc. (NASDAQ:EDSA) shares are flat 2.82% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Edesa Biotech, Inc. trading at a premium to the broader market with a P/E of -5.1. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $18.80, suggesting 176.06% upside. Our AI forecast model points to short-term weakness (-8.52% over two weeks), a medium-term rise (299.27% over three months), and a longer-term gain (275.77% over one year), with expected trading ranges indicating moderate volatility.